Recursion Pharmaceuticals, Inc. (RXRX)

NASDAQ: RXRX · IEX Real-Time Price · USD
9.36
-0.15 (-1.58%)
At close: May 22, 2024, 4:00 PM
9.56
+0.20 (2.14%)
After-hours: May 22, 2024, 7:58 PM EDT
-1.58%
Market Cap 2.15B
Revenue (ttm) 46.24M
Net Income (ttm) -354.11M
Shares Out 230.11M
EPS (ttm) -1.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,448,410
Open 9.52
Previous Close 9.51
Day's Range 9.22 - 9.56
52-Week Range 4.97 - 16.75
Beta 0.85
Analysts Buy
Price Target 17.40 (+85.9%)
Earnings Date May 9, 2024

About RXRX

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; R... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 16, 2021
Employees 500
Stock Exchange NASDAQ
Ticker Symbol RXRX
Full Company Profile

Financial Performance

In 2023, RXRX's revenue was $44.58 million, an increase of 11.88% compared to the previous year's $39.84 million. Losses were -$328.07 million, 37.0% more than in 2022.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for RXRX stock is "Buy." The 12-month stock price forecast is $17.4, which is an increase of 85.90% from the latest price.

Price Target
$17.4
(85.90% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry

BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024. BioHive-2, an NVIDI...

9 days ago - GlobeNewsWire

Recursion Pharmaceuticals CEO Chris Gibson goes one-on-one with Jim Cramer

Recursion Pharmaceuticals Co-Founder and CEO Chris Gibson joins 'Mad Money' host Jim Cramer to talk integrating machine learnings into drug development and partnering with Nvidia.

12 days ago - CNBC Television

We've built an unbiased platform that lets data drive decisions, not us, says Recursion CEO

Recursion Pharmaceuticals Co-Founder and CEO Chris Gibson joins 'Mad Money' host Jim Cramer to talk integrating machine learnings into drug development and partnering with Nvidia.

12 days ago - CNBC Television

Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results

SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates an...

13 days ago - GlobeNewsWire

Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9

SALT LAKE CITY, May 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide bu...

20 days ago - GlobeNewsWire

Recursion to Participate in Upcoming Investor Conferences

SALT LAKE CITY, May 01, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation ...

21 days ago - GlobeNewsWire

Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX

Biotech stocks are having a relatively strong year as investors focus on the growing M&A in the healthcare space. Johnson & Johnson is acquiring Shockwave Medical while Novo Nordisk is buying Catalent...

Other symbols: SANAVKTX
4 weeks ago - Invezz

Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer

Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of Directors Dr. Khan,...

5 weeks ago - GlobeNewsWire

Recursion Publishes Annual Environmental, Social and Governance Report

Provides progress updates in support of long-term commitments focused on reducing greenhouse gas emissions, improving workforce diversity and accelerating community impact. Provides progress updates i...

2 months ago - GlobeNewsWire

Not just Soundhound, these AI stocks are also riding Nvidia wave

Following Nvidia's investment disclosure, SoundHound AI's shares have dramatically increased, tripling in value and boosting its market capitalization to $2.75 billion. The company's success is attrib...

Other symbols: NVDASOUNARMNNOX
2 months ago - Invezz

Recursion Announces Plans to Open New Office in London

Appoints Michael Bronstein as Scientific Advisor and launches recruiting effort to fill the first 20 open roles across technology and biology, establishing a hub for world-class TechBio talent in the ...

2 months ago - GlobeNewsWire

Recursion Hosts Second Annual Rare Disease Day Events for Utah's Rare Disease Community

SALT LAKE CITY, March 01, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, hosted its second annual Rare Di...

2 months ago - GlobeNewsWire

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results

SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates a...

3 months ago - GlobeNewsWire

Recursion to Host Public L(earnings) Call on February 27

SALT LAKE CITY, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide b...

3 months ago - GlobeNewsWire

Nvidia discloses investments in smaller AI firms

Nvidia (NVDA) has disclosed investments made in several emerging AI companies, sparking rallies across these stocks. Among the names benefiting include Soundhound (SOUN), Arm (ARM), and Nanox (NNOX).

Other symbols: NVDAARMNNOXSOUN
3 months ago - Yahoo Finance

Shares of Smaller AI Firms Rise After Nvidia Discloses Investments

Shares of smaller artificial intelligence (AI) firms reportedly experienced a rally Thursday (Feb. 15) after Nvidia, the world's leading AI chipmaker, disclosed its stake in them as of Dec. 31. This m...

Other symbols: NVDANNOXSOUNARM
3 months ago - PYMNTS

Altitude Lab Startups Raise Over $120M in Capital

SALT LAKE CITY, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Altitude Lab today announced that its incubating startups raised over $120M in early-stage funding since commencing operations in 2020. Altitude Lab w...

4 months ago - GlobeNewsWire

Nvidia dives deeper into AI drug development with Amgen, Recursion partnerships

Nvidia Corp. NVDA, +4.72% is doubling down on artificial-intelligence-powered drug discovery and development, announcing expanded partnerships Monday with Amgen Inc. AMGN, +1.26% and Recursion Pharmac...

Other symbols: AMGNNVDA
4 months ago - Market Watch

Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare Conference

Recursion and NVIDIA will host an invite-only event on Wednesday, January 10, where Recursion will provide live demonstrations of LOWE, its new LLM-based software that can perform complex drug discove...

4 months ago - GlobeNewsWire

Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline

Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer

4 months ago - GlobeNewsWire

Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry

Screening libraries will leverage Recursion's MatchMaker tool to identify compounds across Enamine REAL Space predicted to bind to high-value targets. Screening libraries will leverage Recursion's Mat...

5 months ago - GlobeNewsWire

Bayer and Recursion focus research collaboration on Oncology

BERLIN & SALT LAKE CITY--(BUSINESS WIRE)--Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that th...

Other symbols: BAYRY
6 months ago - Business Wire

Bayer and Recursion Focus Research Collaboration on Oncology

Digitally enabled drug discovery for oncology has the potential to accelerate the delivery of new cancer therapies to patients. Drug discovery research collaboration may initiate up to seven oncology ...

6 months ago - GlobeNewsWire

Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology

With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio With additional patient-centric ...

6 months ago - GlobeNewsWire

Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results

SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates a...

6 months ago - GlobeNewsWire